38 results on '"O'Cathail, Sean"'
Search Results
2. Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
3. Improving outcomes for resistant rectal cancer
4. The in-silico feasibility of dose escalated, hypofractionated radiotherapy for rectal cancer
5. NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
6. Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes
7. A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer
8. Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
9. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
10. Patient-reported outcomes in PROSPECT Trial (Alliance N1048) - FOLFOX is not a panacea
11. Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer – A retrospective dosimetry review and feasibility planning study
12. Abstract 3231: Temporal changes in intratumoral and systemic lymphocytes in response to short and long course radiotherapy regimens in locally advanced rectal cancer
13. Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT).
14. The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long‐term outcome in locally advanced rectal cancer.
15. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas
16. Serial sampling of rectal tumors during radiotherapy: A proof-of-concept study.
17. Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomized phase II trial (PRIME-RT).
18. Intensity modulated radiotherapy for rectal cancer in the UK in 2020
19. A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence
20. Stereotactic Body Radiotherapy re-irradiation for locally recurrent rectal cancer: outcomes and toxicity
21. Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity
22. Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy
23. CRISPR-Cas9 Causes Chromosomal Instability and Rearrangements in Cancer Cell Lines, Detectable by Cytogenetic Methods
24. Nrf2 metagene as a prognostic biomarker across all stages of colorectal cancer (CRC).
25. Outcomes following stereotactic body radiotherapy (SBRT) in locally recurrent rectal cancer (LRRC) in a previously irradiated pelvis.
26. Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization
27. Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization
28. Activity of eribulin mesylate in heavily pretreated breast cancer granted accessvia the Cancer Drugs Fund
29. Drug radiotherapy combinations: Review of previous failures and reasons for future optimism
30. Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials
31. Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological Malignancies
32. Ayurveda: alternative or complementary?
33. Multivariate screening of prognostic factors to identify a novel, simple, and objective marker to optimize patient selection and predict survival benefit in early-phase trials.
34. Use of inflammation-based scores to optimize the selection of patients with advanced cancer considered for early-phase clinical trials.
35. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
36. Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.
37. Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1.
38. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.